Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract. In recent decades, there have been significant advances in the understanding of IBD pathophysiology and the development of new treatments.
The International Organisation for the Study of Inflammatory Bowel Diseases (IOIBD) developed the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) programs, which recommend specific treatment goals for UC and CD in children and adults. These goals include clinical response and remission, endoscopic healing, normalization of C-reactive protein/erythrocyte sedimentation rate and fecal calprotectin, prevention of disability, restoration of quality of life, and normal growth in children.
The current mainstay treatments for IBD include immunomodulators, biologics (anti-tumor necrosis factor alpha (TNF-α) agents being the most commonly used), and other monoclonal antibodies such as anti-integrins and anti-interleukins (IL-12/23). However, primary and secondary loss of response to these therapies is a major recurring issue, with often diminishing returns in terms of efficacy for the next line of therapies prescribed.
Recently, there has been an influx of new and emerging medications entering the market that are showing promising efficacy results in patients with moderate-to-severe IBD who have previously failed to respond to multiple drugs. These novel and emerging therapies include:
These novel and emerging therapies offer new hope for patients with moderate-to-severe IBD who have previously failed to respond to multiple drugs. More research is needed to confirm their long-term safety and efficacy, but they have the potential to revolutionize the treatment of IBD.
See the article:
Kumar A, Smith PJ. Horizon scanning: new and future therapies in the management of inflammatory bowel disease.
eGastroenterology 2023; 1: e100012. doi: 10.1136/egastro-2023-100012
About the eGastroenterology
eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery).
For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).
Sign-up to Email Alerts for eGastroenterology : https://emails.bmj.com/k/Bmj/jausu/egastroenterology
eGastroenterology
Horizon scanning: new and future therapies in the management of inflammatory bowel disease